Sling Therapeutics
CompanyUnited States
Sling Therapeutics develops one asset, in phase 3 (linsitinib in thyroid eye disease). Mostly small molecule acting on Insulin/IGF-1 signalling, IGF1R and INSR; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 1
- Signal
Pipeline
1Inhibits IGF-1 and insulin receptor tyrosine kinases, blocking downstream signaling.
Phase 3, Small molecule, Insulin/IGF-1 signalling, IGF1R, thyroid eye disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Signals1
- Similar companies6